Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Perspective Therapeutics Inc.

Healthcare US CATX

3.05USD
0.10(3.39%)

Last update at 2026-06-22T20:00:00Z

Day Range

2.953.12
LowHigh

52 Week Range

1.966.16
LowHigh

Fundamentals

  • Previous Close 2.95
  • Market Cap529.04M
  • Volume2347872
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-110.32000M
  • Revenue TTM0.88M
  • Revenue Per Share TTM0.01
  • Gross Profit TTM -83.33100M
  • Diluted EPS TTM-1.41

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2023-06-30 2022-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2023-06-30 2022-12-31
Income before tax -103.91400M -81.37600M -40.10600M -14.67000M -14.67000M
Minority interest - - - - -
Net income -103.12100M -79.27900M -46.50800M -14.67000M -14.67000M
Selling general administrative 30.23M 26.61M 20.97M 10.87M 10.87M
Selling and marketing expenses - - 0.10M 3.23M 3.23M
Gross profit - - 1.43M 1.63M 1.63M
Reconciled depreciation 3.25M 2.31M 0.95M - -
Ebit 5.88M - -40.94100M -15.18200M -15.18200M
Ebitda 9.14M 10.46M -39.96000M -14.83800M -14.83800M
Depreciation and amortization 3.25M - 0.98M 0.34M 0.34M
Non operating income net other - - - - -
Operating income 9.14M 10.46M -40.94100M -15.18200M -15.18200M
Other operating expenses - - 42.38M 22.90M 22.90M
Interest expense 0.38M 0.05M 0.08M - 0.12M
Tax provision -0.79300M -2.09700M -2.65100M - -
Interest income 8.11M 10.52M 0.93M - -
Net interest income 7.74M 10.47M 0.85M - -
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -0.79300M -2.09700M -2.65100M - -0.11900M
Total revenue 0.00000M 0.00000M 1.43M 7.10M 7.10M
Total operating expenses 114.45M 92.34M 42.38M 17.43M 17.43M
Cost of revenue - - - 5.47M 5.47M
Total other income expense net -113.05000M -91.83500M 0.83M 0.51M 0.51M
Discontinued operations - - - - -
Net income from continuing ops -103.63500M -78.33000M -37.45500M - -
Net income applicable to common shares - - - - -
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2023-06-30 2022-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2023-06-30 2022-12-31
Total assets 266.97M 341.10M 97.89M 58.09M 58.09M
Intangible assets 40.00M 50.00M 50.35M 0.09M 0.09M
Earning assets - - - - -
Other current assets 3.65M 4.13M 6.42M 6.69M 6.69M
Total liab 59.94M 50.43M 22.71M 3.45M 3.45M
Total stockholder equity 207.03M 290.67M 75.18M 54.64M 54.64M
Deferred long term liab - - - - -
Other current liab 1.46M 5.48M 9.46M 1.14M -0.40600M
Common stock 0.07M 0.07M 0.28M 0.14M 0.14M
Capital stock 0.07M 0.07M 0.28M - -
Retained earnings -334.84000M -231.71900M -152.44000M -105.93200M -105.93200M
Other liab - - - - -
Good will - 0.00000M 24.06M - -
Other assets - - - 2.58M 2.58M
Cash 30.63M 61.58M 9.24M 20.99M 20.99M
Cash and equivalents - - - - -
Total current liabilities 28.68M 18.23M 15.66M 2.68M 2.68M
Current deferred revenue 26.60M 1.40M - - -
Net debt -29.00100M -57.51800M -6.68700M -20.99300M -20.99300M
Short term debt 0.62M 1.01M 0.10M - 0.27M
Short long term debt 0.06M 0.05M 0.05M - -
Short long term debt total 1.63M 4.06M 2.55M - 0.52M
Other stockholder equity 541.69M 522.37M 227.34M 160.43M 160.43M
Property plant equipment - - - - -
Total current assets 148.39M 231.16M 16.84M 53.22M 53.22M
Long term investments 0.28M 0.32M 0.13M - -
Net tangible assets - - - - -
Short term investments 114.11M 165.34M 0.00000M 22.76M 22.76M
Net receivables 0.00600M 0.12M 1.18M 1.36M 1.36M
Long term debt 1.57M 1.62M 1.68M - -
Inventory - - - 1.41M 1.41M
Accounts payable 20.51M 10.34M 6.11M 1.54M 1.54M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.11M -0.05100M - - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.49M 0.41M 0.18M -2.29800M -2.29800M
Deferred long term asset charges - - - - -
Non current assets total 118.58M 109.94M 81.05M 2.30M 2.30M
Capital lease obligations 1.63M 2.38M 0.83M - -
Long term debt total - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2023-06-30 2022-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2023-06-30 2022-12-31
Investments 54.11M -218.93100M 24.37M - -
Change to liabilities - - - - -
Total cashflows from investing activities 41.23M -218.93100M 24.37M - -57.67800M
Net borrowings -0.05200M -0.04800M -0.06800M - -
Total cash from financing activities 10.30M 289.38M 0.79M 0.06M 0.06M
Change to operating activities - - - - -
Net income -103.12100M -79.27900M -46.50800M -14.67000M -14.67000M
Change in cash -30.95100M 52.16M -46.65200M 0.18M 0.18M
Begin period cash flow 61.58M 9.42M 21.18M 55.89M 55.89M
End period cash flow 30.63M 61.58M 9.42M 56.07M 56.07M
Total cash from operating activities -82.48400M -18.29400M -36.91300M -12.17200M -12.17200M
Issuance of capital stock 9.99M 275.93M 0.36M - -
Depreciation 3.25M 2.31M 0.95M 0.34M 0.34M
Other cashflows from investing activities -0.13500M 78.99M -0.01800M - -57.37600M
Dividends paid - - - - -
Change to inventory 0.00000M 0.01M 0.36M -0.15200M -0.15200M
Change to account receivables 0.11M 1.05M -0.42600M 0.49M 0.49M
Sale purchase of stock - - - - -
Other cashflows from financing activities 10.30M 289.38M 0.49M 0.06M 0.06M
Change to netincome - - - - -
Capital expenditures 12.75M 54.41M 1.07M 0.30M 0.30M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 1.68M 31.81M 2.30M 0.34M 0.34M
Stock based compensation 8.97M 5.39M 3.74M 1.34M 1.34M
Other non cash items 9.21M 55.39M 5.27M 0.47M 0.47M
Free cash flow -95.23300M -72.70800M -37.98500M -12.47400M -12.47400M

Peer Comparison

Sector: Healthcare Industry: Medical Devices

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
CATX
Perspective Therapeutics Inc.		 0.10 3.39% 3.05 - 25.71 598.46 2.56 68.73 -21.9081
ABT
Abbott Laboratories		 -0.58 0.66% 87.83 25.97 17.24 3.57 3.20 3.81 16.75
SYK
Stryker Corporation		 -3.11 1.01% 304.69 44.07 24.94 5.51 6.12 6.05 25.73
MDT
Medtronic PLC		 -0.07 0.09% 79.27 26.60 15.87 3.35 2.08 3.90 14.12
BSX
Boston Scientific Corp		 -0.96 2.12% 44.33 31.49 17.24 4.41 3.65 4.88 19.19

Reports Covered

Stock Research & News

View All

Profile

Perspective Therapeutics, Inc., a radiopharmaceutical development company, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. It discovers and develops its initial drug candidate VMT-a-NET that is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta emitting therapy; VMT01, which is in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma; and PSV359, a targeted alpha therapy targeting fibroblast activation protein alpha. The company also develops Pluvicto, a betaemitting radioligand therapy to treat progressive prostate-specific membrane antigen (PSMA) positive metastatic castration-resistant prostate cancer. It has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 2004 and is headquartered in Seattle, Washington.

Perspective Therapeutics Inc.

2401 Elliott Avenue, Seattle, WA, United States, 98121

Key Executives

Name Title Year Born
Mr. Johan M. Spoor CEO & Director 1972
Mr. Jonathan R. Hunt CFO and Principal Financial & Accounting Officer 1967
Dr. Markus Puhlmann M.B.A., M.D. Chief Medical Officer 1966
Mr. Shane Cobb Executive Vice President of Operations NA
Dr. Michael K. Schultz Ph.D. Chief Science Officer NA
Ms. Annie J. Cheng Vice President of Investor Relations 1976
Mr. Andrew Bright Executive Vice President of Brachytherapy NA
Mr. Amos Hedt BA, PGradDip Chief Business Strategy Officer NA
Dr. Frances L. Johnson M.D. Chief Innovation Officer NA
Mr. David Hauser Ph.D. Senior Vice President of Clinical Operations NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions